查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718940

日本的造影超音波市場評估:各產品，各用途，各終端用戶，各地區，機會，預測，2019年～2033年度

Japan Contrast Enhanced Ultrasound Market Assessment, By Product, By Application, By End-user, By Region, Opportunities and Forecast, FY2019-FY2033F
出版日期: | 出版商: Markets & Data | 英文 124 Pages | 商品交期: 3-5個工作天內

價格

日本造影超音波市場預計將從2025年的9,044萬美元成長到2033年的1.5086億美元，在2026-2033年的預測期內，複合年增長率為6.61%。日本肝臟和心血管疾病的發生率不斷上升，推動了對造影增強超音波 (CEUS) 的需求，使其成為更安全、非侵入性的診斷工具。隨著臨床醫生和患者意識的提高，加上超音波技術的進步，加速了其在醫院和影像中心的應用。此外，政府對無輻射成像的支持與CEUS的優勢相符，進一步鼓勵其融入常規診斷。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 日本的造影超音波市場展望(2019年～2033年)

  • 市場規模分析與預測
    • 各金額
    • 各數量
  • 市場佔有率分析與預測
    • 各產品
      • 設備
      • 顯影劑
      • 軟體和服務
    • 各用途
      • 診斷用途
      • 治療用途
    • 各終端用戶
      • 醫院·外科中心
      • 診斷影像中心
      • 門診病人手術中心
      • 其他
    • 各地區
      • 北部(北海道·東北)
      • 中部(關東·中部)
      • 南部(關西，中國，四國，九州·沖繩)
    • 各企業市場佔有率分析(前五名公司和其他-各金額，2025年)
  • 2025年，市場地圖分析
    • 各產品類型
    • 各用途
    • 各終端用戶
    • 各地區

第6章 價值鏈分析

第7章 需求供給分析

第8章 進口和出口的分析

第9章 波特的五力分析

第10章 大環境分析

第11章 價格分析

第12章 市場動態

  • 推動市場要素
  • 市場課題

第13章 市場趨勢與發展

第14章 法規結構和革新

第15章 競爭情形

  • 前五名市場領導公司的競爭矩陣
  • 前五大企業的SWOT分析
  • 市場前十名的主要企業的形勢
    • Lantheus Medical Imaging, Inc.
      • 公司概要
      • 主要經營團隊
      • 產品和服務
      • 財務狀況(報告那樣)
      • 主要市場的著重和地理存在感
      • 最近的趨勢/合作/夥伴關係/合併和收購
    • GE HealthCare Technologies Inc.
    • Bracco Imaging SPA
    • Philips Holding USA Inc.
    • Siemens Medical Solutions USA, Inc.
    • Mindray Medical International Limited
    • Canon USA, Inc.
    • Esaote SPA
    • Samsung Electronics Co., Ltd
    • Guerbet SA

以上公司並非依市佔率排序，且可能根據研究期間所獲得的資訊而有所變動。

第16章 策略性建議

第17章 關於調查公司·免責聲明

Product Code: MX13065

Japan contrast enhanced ultrasound market is projected to witness a CAGR of 6.61% during the forecast period FY2026-FY2033, growing from USD 90.44 million in FY2025 to USD 150.86 million in FY2033. Growing prevalence of liver and cardiovascular diseases in Japan is driving demand for Contrast Enhanced Ultrasound (CEUS) as a safer, non-invasive diagnostic tool. Rising awareness among clinicians and patients, combined with advancements in ultrasound technology, is boosting its adoption across hospitals and imaging centers. Additionally, government support for radiation-free imaging aligns with CEUS benefits, further encouraging its integration into routine diagnostics.

Rising Prevalence of Chronic Diseases and Geriatric Population

Japan is experiencing an increase in its aging population alongside a rising incidence of chronic illnesses, including liver, kidney, and cardiovascular diseases. Contrast-Enhanced Ultrasound (CEUS) has emerged as a favored diagnostic method in these fields due to its non-invasive nature, lack of ionizing radiation, and excellent safety profile, which is particularly advantageous for elderly and high-risk patients. It offers real-time vascular imaging, enabling healthcare providers to identify lesions and tumors with greater precision. The growing need for regular diagnostic assessments in chronic diseases further drives the adoption of CEUS. Moreover, Japan's healthcare system emphasizes early disease detection to minimize long-term care expenses, prompting hospitals to incorporate CEUS into their diagnostic offerings. For instance, according to Japan's Ministry of Internal Affairs and Communications, as of 2023, seniors (65+) made up 29.1% of the total population, highlighting the pressing need for chronic disease management solutions.

Technological Advancements and Integration with AI Fueling Growth

In Japan, Contrast-Enhanced Ultrasound (CEUS) is undergoing swift advancements, particularly through the incorporation of artificial intelligence (AI) and advanced imaging software. These innovations improve image quality, lessen reliance on operators, and facilitate real-time analysis, thereby increasing the efficiency and applicability of CEUS. Japanese companies are channeling investments into CEUS systems that feature AI-based lesion detection, automated quantification, and motion correction capabilities. The enhanced precision and diagnostic reliability provided by these systems are promoting their acceptance in hospitals and diagnostic facilities. Moreover, AI enhances the reproducibility of CEUS results-an important factor for widespread clinical implementation. These innovations align with Japan's broader focus on smart healthcare technologies to address labor shortages and improve patient outcomes. For example, Canon U.S.A., Inc., a leading global supplier of imaging solutions, has launched Aplio beyond, a versatile ultrasound system that combines clinical excellence, operational efficiency, and ergonomic design in a compact, quiet, and eco-friendly package. Tailored for ultrasound specialists working in hospitals, busy imaging centers, and advanced practices that manage substantial workloads and varied patient populations, it provides outstanding imaging capabilities for routine assessments, specialized investigations, and complex procedures.

Increasing Use of CEUS in Oncology and Liver Imaging

CEUS is gaining significant traction in oncology diagnostics, especially for liver cancer, which has high incidence rates in Japan. It offers superior lesion characterization, early tumor detection, and post-treatment follow-up capabilities, often outperforming CT or MRI in certain contexts. Given its ability to visualize micro-vascularization without nephrotoxic contrast agents, CEUS is now commonly used for patients with renal impairments-common among cancer patients. Hospitals are increasingly adopting CEUS for liver, breast, and prostate cancer screening, due to its repeatability and low risk. Moreover, CEUS-guided biopsies and ablations have improved precision and outcomes in cancer treatment. For example, in late 2023, researchers at Kyoto University published clinical outcomes showing that CEUS significantly improved the detection rate of hepatocellular carcinoma (HCC) in high-risk Japanese patients compared to conventional ultrasound.

Future Market Scenario (FY2026 - FY2033F)

The Japan Contrast Enhanced Ultrasound (CEUS) market is poised for strong growth due to increasing applications in liver disease diagnosis, oncology, and cardiovascular imaging. As Japan faces a high burden of chronic liver conditions and an aging population, demand for non-invasive, radiation-free diagnostic tools is surging. CEUS offers real-time, high-resolution imaging with minimal side effects, making it ideal for repeated use, especially among elderly and vulnerable patients. Technological advancements, rising healthcare expenditure, and a growing preference for point-of-care imaging are expected to further propel adoption. Additionally, collaborations between Japanese medical institutions and global imaging companies are accelerating CEUS-related clinical trials and technology integration, positioning the market for long-term growth in diagnostic and therapeutic applications

.

Key Players Landscape and Outlook

Key players in the contrast enhanced ultrasound industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, Canon U.S.A., Inc. partnered with Olympus to introduce their newest ultrasound device, the Aplio i800 EUS. This hybrid system is especially proficient in identifying small lesions in the pancreas, as stated by Akihiro Sano, the general manager of ultrasound systems at Canon during a press briefing in January 2024.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Japan Contrast Enhanced Ultrasound Market Outlook, FY2019-FY2033F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Equipment
      • 5.2.1.2. Contrast Agents
        • 5.2.1.2.1. Molecule-Targeted Microbubbles
        • 5.2.1.2.2. Nanoparticle Microbubbles
      • 5.2.1.3. Software and Services
    • 5.2.2. By Application
      • 5.2.2.1. Diagnostic Applications
        • 5.2.2.1.1. Nephrology
        • 5.2.2.1.2. Cardiology
        • 5.2.2.1.3. Others
      • 5.2.2.2. Therapeutic Applications
        • 5.2.2.2.1. Cardiology
        • 5.2.2.2.2. Oncology
        • 5.2.2.2.3. Vascular
        • 5.2.2.2.4. Others
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals And Surgical Centers
      • 5.2.3.2. Diagnostic Imaging Centers
      • 5.2.3.3. Ambulatory Surgery Center
      • 5.2.3.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. North [Hokkaido and Tohoku]
      • 5.2.4.2. Central [Kanto and Chubu]
      • 5.2.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
  • 5.3. Market Map Analysis, FY2025
    • 5.3.1. By Product Type
    • 5.3.2. By Application
    • 5.3.3. By End-user
    • 5.3.4. By Region

6. Value Chain Analysis

7. Demand Supply Analysis

8. Import and Export Analysis

9. Porter's Five Forces Analysis

10. PESTLE Analysis

11. Pricing Analysis

12. Market Dynamics

  • 12.1. Market Drivers
  • 12.2. Market Challenges

13. Market Trends and Developments

14. Regulatory Framework and Innovation

15. Competitive Landscape

  • 15.1. Competition Matrix of Top 5 Market Leaders
  • 15.2. SWOT Analysis for Top 5 Players
  • 15.3. Key Players Landscape for Top 10 Market Players
    • 15.3.1. Lantheus Medical Imaging, Inc.
      • 15.3.1.1. Company Details
      • 15.3.1.2. Key Management Personnel
      • 15.3.1.3. Products and Services
      • 15.3.1.4. Financials (As Reported)
      • 15.3.1.5. Key Market Focus and Geographical Presence
      • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 15.3.2. GE HealthCare Technologies Inc.
    • 15.3.3. Bracco Imaging S.P.A.
    • 15.3.4. Philips Holding USA Inc.
    • 15.3.5. Siemens Medical Solutions USA, Inc.
    • 15.3.6. Mindray Medical International Limited
    • 15.3.7. Canon U.S.A., Inc.
    • 15.3.8. Esaote S.P.A
    • 15.3.9. Samsung Electronics Co., Ltd
    • 15.3.10. Guerbet SA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Japan Contrast Enhanced Ultrasound Market, By Value, In USD Million, FY2019-FY2033F
  • Figure 2. Japan Contrast Enhanced Ultrasound Market, By Volume, In Million Units, FY2019-FY2033F
  • Figure 3. Japan Contrast Enhanced Ultrasound Market Share (%), By Product, FY2019-FY2033F
  • Figure 4. Japan Contrast Enhanced Ultrasound Market Share (%), By Application, FY2019-FY2033F
  • Figure 5. Japan Contrast Enhanced Ultrasound Market Share (%), By End-user, FY2019-FY2033F
  • Figure 6. Japan Contrast Enhanced Ultrasound Market Share (%), By Region, FY2019-FY2033F
  • Figure 7. By Product Map-Market Size (USD Million) & Growth Rate (%), FY2025
  • Figure 8. By Application Map-Market Size (USD Million) & Growth Rate (%), FY2025
  • Figure 9. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2025
  • Figure 10. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025